Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?

Pfizer (PFE) is expected to report Q2 2025 earnings of $0.58 per share, a 3.3% year-over-year decline, on revenues of $13.78 billion, up 3.7%, when it releases results on August 5. Despite the anticipated EPS decline, the company holds a positive Zacks Earnings ESP of +1.43% and a Zacks Rank #3 (Hold), indicating a strong probability of an earnings beat, a trend consistent with its performance in the past four quarters. This suggests Pfizer is a compelling candidate for a positive earnings surprise, potentially influencing its near-term stock trajectory.

Analysis

Pfizer (PFE) is approaching its June 2025 quarterly earnings report with a mixed but statistically favorable outlook. The consensus forecast anticipates a 3.3% year-over-year decline in earnings to $0.58 per share, contrasting with an expected 3.7% increase in revenue to $13.78 billion. Despite the projected earnings contraction and a minor 0.23% downward revision to the consensus EPS over the last 30 days, a key predictive indicator suggests a strong likelihood of an earnings beat. The company holds a positive Zacks Earnings ESP of +1.43%, stemming from more recent, bullish analyst estimates, combined with a Zacks Rank #3 (Hold). This specific combination has historically led to a positive earnings surprise approximately 70% of the time, a pattern consistent with Pfizer's performance over the last four consecutive quarters, which included a notable +43.75% surprise in the prior period. While these metrics position Pfizer as a compelling candidate for a positive short-term catalyst, the ultimate sustainability of any stock price movement will hinge on management's forward-looking guidance and commentary on underlying business conditions during the August 5th earnings call.

Key Decisions for Investors

• Given the +1.43% Earnings ESP and a strong history of positive surprises, investors with a higher risk tolerance could consider a short-term tactical position to capitalize on a potential post-earnings rally.
• Investors should scrutinize the full earnings report and management's guidance, as a headline EPS beat may be overshadowed by the underlying year-over-year earnings decline or a cautious outlook.
• Monitor the company's revenue growth drivers and margin commentary closely, as the divergence between expected revenue growth (+3.7%) and earnings decline (-3.3%) points to potential pressure on profitability that needs to be assessed for long-term positions.